Serina Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SER NYSE American 2836 www.serinatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Serina Therapeutics, Inc.

Epigenetic Reprogramming Longevity Therapeutics Global Market Report 2026 | Capture $16.14B AI and Cell Reprogramming Growth as Retro Biosciences, Altos Labs and NewLimit Lead - Oct 30th, 2026 8:41 am
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress" - Sep 23rd, 2026 2:18 pm
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Sep 10th, 2026 2:05 pm
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2 - Sep 9th, 2026 5:45 am
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - Aug 13th, 2026 2:15 pm
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - Jul 24th, 2026 4:00 am
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Jul 23rd, 2026 4:00 am
Serina Therapeutics Appoints Farrell Simon to its Board of Directors - Jul 22nd, 2026 2:30 pm
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Jul 9th, 2026 10:10 am
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program - Jun 30th, 2026 7:01 am
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - May 14th, 2026 2:20 pm
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - May 13th, 2026 6:06 am
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit - Apr 7th, 2026 4:00 am
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan - Apr 2nd, 2026 2:13 pm
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Mar 18th, 2026 2:10 pm
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Feb 24th, 2026 2:05 pm